Abstract: Method for detecting spatial coupling comprising the steps of: a. providing a set of data, b. identifying and segmenting a first and a second sets of objects of interest, wherein the objects of the second set are assimilated to punctual objects, c. determining, using a level set function, an expected number of objects of the second set present within a specified range of distances to at least one given object of the first set in case there were no interactions between said at least one given object of the first set and the objects of the second set, d. determining, using a level set function, an actual number of objects of the second set within the same range of distances to the at least one given object of the first set, and e. comparing said expected amount and said determined amount.

Abstract: A recombinant lentiviral vector comprising a coding sequence for an OR protein fused to a coding sequence for a fluorescent protein or a subunit of a fluorescent protein, and a promoter active in human cells operatively linked to the coding sequences. A recombinant lentivirus comprising a recombinant genome comprising an RNA that generates an ANCH sequence upon retrotranscription. A recombinant eukaryotic cell comprising a genomically integrated DNA copy of the recombinant lentiviral vector.

Abstract: The invention relates to Interleukin-2 (IL-2) variants for the prevention or treatment of immune disorders, including with no limitations allergic, autoimmune, chronic or acute inflammatory and infectious diseases; graft-versus-host disease; graft rejection and cancer. The invention also relates to the use of said IL-2 variants for the screening of anti-IL-2 antibodies with pro-T-effector or pro-T-regulatory cell activity.

Abstract: The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.

Abstract: The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide. In particular, the invention relates to antigenic fusion polypeptides of malaria parasites wherein said antigenic polypeptides exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites or a sterile response. Such identified antigenic fusion polypeptides may thus constitute active ingredients suitable for the design of a vaccine candidate, in particular a vaccine suitable for a human host.

Abstract: The present invention provides protected tetrasaccharides, their process of preparation and their use in the synthesis of oligosaccharides, in particular fragments of O-antigens from Shigella flexneri, for example of serotype 1a, 1b, 2a, 2b, 3a, X, 4a, 4b, 5a, 5b, 7a or 7b.

Abstract: The present invention is in the field of bioluminescence in biology and/or medicine. In particular, the invention provides imidazopyrazine derivatives, processes for preparation thereof, and their uses as luciferins.

Abstract: The invention relates to a method for generating protein sequences in an autoregressive neural network comprising an encoder and a decoder, the decoder comprising an autoregressive module, the method comprising: obtaining a latent code and inputting the latent code into the autoregressive module; obtaining probabilities from the autoregressive module, the obtained probabilities representing probabilities for amino acids to be selected at locations of the sequence; and generating an ordered sequence of amino acids from the obtained probabilities, wherein the autoregressive module is such that, for a location of the sequence, the probabilities associated with amino acids to be selected for the location in the sequence are determined as a function of probabilities of amino acids to be selected for previous locations in the sequence and wherein the autoregressive neural network has been trained end-to-end with the encoder, the encoder making it possible to encode protein sequences in a latent space as late

Abstract: The invention is in the field of prevention or treatment of diseases, in particular infectious diseases, and more particularly in the field of multivalent vaccines. The inventors characterized 5? copy-back DI-RNAs produced by recombinant MV strains, including rMV-based vaccines and wild-type MV (wt-MV). The efficiency of these DI-RNAs productions in different cell types was compared. For the first time 5? copy-back DI-RNAs specific binding to RIG-I, MDA5 and LGP2 was assessed and linked to functional outcome in type-I IFN signalling. The inventors provide a composition of products comprising at least (i) a mixture of particles of a rescued recombinant MV-derived virus encoding at least one antigen (ii) a recombinant and/or purified protein, comprising at least one antigen. Regardless of the presentation of the products, and in particular regardless of whether the products are separated or readily separable or presented as a mixture.

Abstract: The invention relates to methods of diagnosis or detection of Moissiacense virus, a novel orthobunyavirus causing human encephalitis, comprising determining the presence of at least one nucleic acid or protein of said virus or antibodies thereto, in a biological sample. The invention also relates to the various diagnostic agents derived from the viral nucleic acids or proteins, in articular nucleic acid primers and probes, antigens and antibodies, and their use for the diagnosis of Moissiacense virus infection and associated disease, in particular encephalitis. The invention further relates to antigens derived from the viral proteins as vaccine for the prevention of Moissiacense virus infection and associated disease, in particular encephalitis.

Abstract: The invention relates to chimeric Plasmodium antigenic polypeptides derived from pre-erythrocytic (PE) antigens and associated in a fusion polypeptide. In particular, the invention relates to antigenic fusion polypeptides of malaria parasites wherein said antigenic polypeptides exhibit a protective effect, especially that of eliciting a protective immune response in a host against challenge by Plasmodium sporozoites or a sterile response. Such identified antigenic fusion polypeptides may thus constitute active ingredients suitable for the design of a vaccine candidate, in particular a vaccine suitable for a human host.

Abstract: The invention relates to mutant DNA polymerases of the Pol theta subfamily capable of performing non-templated nucleic acid extension, or of a functional fragment of such a polymerase, methods of producing these mutant DNA polymerases, kits and methods of using these mutant DNA polymerases.

Abstract: A computer-implemented and a device for analysis of a digital cytology slide of a biological sample. The biological sample having been previously collected from a subject suspected to be suffering from bladder cancer, the device including: at least one input configured to receive at least one digital cytology slide obtained from the biological sample; at least one processor configured to: detect cells of interest from the at least one digital cytology image; for each cell of interest, compute a features vector including at least one feature calculated on each cell of interest; define a bag of k instances for each digital cytology slide; calculating a global prediction score representative of a probability of presence of bladder cancer and/or a stage of bladder cancer for the subject; at least one output configured to provide the global prediction score.

Abstract: The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease. The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject. The subject invention also provides new bacteriophage strains.

Abstract: Multiplexable microfluidic culture chamber for imaging monolayer growth of single cells The present invention relates generally to a microfluidic device (1a, 1b), particularly for use in single cell analysis. More specifically, the present invention relates to a microfluidic device (1a, 1b) comprising at least one chamber (10), in particular at least two chambers (10) comprising a deformable membrane (16) and having a structure and geometry configured to enable formation of two-dimensional cell culture, in particular two-dimensional cell growth area (29), and imaging thereof over a growth period or a time period sufficient to analyze cells, in particular to monitor cell growth. The microfluidic device (1a, 1b) allows for multi-condition operation of single-cell screening at high spatiotemporal resolution. The present invention also relates to methods for fabrication and use of such devices.

Abstract: The present invention is directed to an isolated synthetic tripeptide of formula H-D-Phe-N-Methyl-L-Val-L-Ala-OMe (SEQ ID NO: 1), or a derivative thereof, and to the corresponding lipotripeptides, which are specific to Mycobacterium avium subsp. paratuberculosis (Map) S-type strain, as well as derivatives and conjugates thereof. The invention also concerns the use of these antigens in different methods and tests for detecting Map infection, especially by detecting humoral response and cell mediated response of infected animals. The invention is also directed to a genetic signature of Map and a mass spectrometry and NMR spectroscopy signature of Map presence or infection.

Abstract: Lachnospiraceae spp and Ruminococcus lactaris new strains of bacteria for use solely or in combination, in the treatment and prevention of memory decline in an individual, in particular declines of aging or Alzheimer's disease-related origin. Compositions, in particular, an oral composition, including the Lachnospiraceae spp and Ruminococcus lactaris strains and uses thereof.

Abstract: A dual AAV vector strategy encoding isoform 5 of otoferlin cDNA that has been split into two expression cassettes both packaged in—and delivered by—an AAV8 capsid can efficiently deliver the otoferlin cDNA to the inner hair cell (IHC). Moreover, the use of the CMV promoter in one of the two AAV8 vectors provides a significant expression of otoferlin in these particular cells. As the AAV serotype and the type of promoter used are two key elements that have a significant effect on the transduction efficiency, this vector system provides optimal therapeutic benefit in patients suffering from DFNB9 deafness. To further improve this therapeutic effect, otoferlin-encoding dual vector constructs to identify enhanced transfection rate and a very effective in vitro and in vivo otoferlin expression in mature cochlea of DFNB9 mice models, leading to the restoration of their hearing.

Abstract: The invention relates to the diagnosis of a SARS-associated coronavirus, such as a SARS-CoV-2 infection and SARS-CoV-1 infection, using the N_SARS-CoV-1 and N_SARS-CoV-2 proteins and antibodies binding to these proteins. The invention reagents, methods and kits for the detection of a SARS-associated coronavirus.

Abstract: The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike(S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.